Physician

Urology

Dr. Daniel Theodorescu, MD

Doctor Daniel Theodorescu, MD works in the field of Urology. He received 1 awards: "Elected Member". Daniel Theodorescu is also published. He has 25 publications published. The lastest publication: "Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.'

Publications

Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple Cancers.
Loss of glycogen debranching enzyme AGL drives Bladder tumor growth via induction of hyaluronic acid synthesis.
The RAS-RAL axis in Cancer: evidence for mutation-specific selectivity in non-small cell lung Cancer.
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
Cancer. TERT promoter mutations and telomerase reactivation in urothelial Cancer.
RhoC is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.
Novel neoadjuvant therapy paradigms for Bladder cancer: Results from the National Cancer Center Institute Forum.
Decade in review-Bladder cancer: International progress: from cytology to genomics.
Discovery and characterization of small molecules that target the GTPase Ral.
Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer.
Bladder cancer: Bladder preservation-learning what we don't know.
Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease.
Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Robust prognostic gene expression signatures in Bladder cancer and lung adenocarcinoma depend on cell cycle related genes.
Pharmacogenomics in Bladder cancer.
A cell of origin gene signature indicates human Bladder cancer has distinct cellular progenitors.
Contributions of KRAS and RAL in Non-Small-Cell Lung Cancer Growth and Progression.
Telomerase in Bladder Cancer: Back to a Better Future?
Translation initiation factor eIF3b expression in human Cancer and its role in tumor growth and lung colonization.
Clinical opportunities and challenges in targeting tumour dormancy.
Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status.
One step closer to targeting RAS.
Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian Cancer.

Schools

Queen39s University Kingston Ontario Canada
University Of Toronto
Memorial SloanKettering Cancer Center Program

Procedures Preformed

Cystectomy
Cystourethroscopy and Transurethral Resection of Bladder Neck
Prostate Removal

Conditions Treated

Bladder Cancer
Chronic Kidney Diseases
Elevated PSA (Prostate Specific Antigen)
Prostate Cancer
View All

Doctors Specialties

Urology

Accepted Insurances

Aetna HMO
Choice Plus POS II
Pathway X Bronze Direct CACA IN HIX
Anthem Blue Cross Blue Shield PPO
Blue Card PPO
Cigna HMO
Cigna PPO
Great West Healthcare-Cigna PPO
LocalPlus
Open Access Plus
Cofinity PPO
First Health (Coventry Health Care) PPO
Medicare MCR
MultiPlan PPO
PHCS Network PPO
Heritage Signature
Choice Plus POS
Navigate HMO
Navigate POS
Options PPO
United Healthcare

Awards

Elected Member

Hospital

University of Colorado Hospital

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Paul D. Maroni, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Shandra S. Wilson, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert J. Snyder, MD
	Dr. Ty T. Higuchi, MD This Doctor is OpenDoctor Recommended.
	Dr. Laura B. Cornwell, MD
	Dr. Nicholas G. Cost, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Brian T. Caldwell, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert J. Larke, MD
	Dr. Kyle O. Rove, MD This Doctor is OpenDoctor Recommended.
	Dr. Joshua D. Spendlove, MD This Doctor is OpenDoctor Recommended.
	Dr. Trevor T. Wild, MD This Doctor is OpenDoctor Recommended.